Elsevier

Drug and Alcohol Dependence

Volume 177, 1 August 2017, Pages 307-314
Drug and Alcohol Dependence

Full length article
Association between process measures and mortality in individuals with opioid use disorders

https://doi.org/10.1016/j.drugalcdep.2017.03.033Get rights and content

Highlights

Abstract

Background

Individuals with opioid use disorders have high rates of mortality relative to the general population. The relationship between treatment process and mortality is unknown.

Aim

To examine the association between 7 process measures and 12- and 24-month mortality.

Methods

Retrospective cohort study of patients with opioid use disorders who received care from the Veterans Administration between October 2006 and September 2007. Logistic regression models were used to examine the association between 12 and 24-month mortality and 7 patient-level process measures, while risk-adjusting for patient characteristics. Process measures included quarterly physician visits, any opioid use disorder pharmacotherapy, continuous pharmacotherapy, psychosocial treatment, Hepatitis B/C and HIV screening, and no prescriptions for benzodiazepines or opioids. We conducted sensitivity analyses to examine the robustness of our findings to an unobserved confounder.

Results

Among individuals with opioid use disorders, not being prescribed opioids or benzodiazepines, receipt of any psychosocial treatment and quarterly physician visits were significantly associated with lower mortality at both 12 and 24 months, but Hepatitis and HIV screening, and measures related to opioid use disorder pharmacotherapy were not. Sensitivity analyses indicated that the difference in the prevalence of an unobserved confounder would have to be unrealistically large given the observed data, or there would need to be a large effect of the confounder, to render these findings non-significant.

Conclusions and relevance

This is the first study to show an association between process measures and mortality in patients with opioid use disorders and provides initial evidence for their use as quality measures.

Introduction

Opioid use disorders (OUDs), including both heroin and prescription opioid use disorders, are associated with high rates of mortality both in the United States and worldwide (Degenhardt et al., 2011, Degenhardt et al., 2014a, Gomes et al., 2014, Martins et al., 2015, Rudd et al., 2016b). Mortality risks for individuals with opioid use disorders range from 6 to 20 times higher than the general population, and opioid-related mortality has increased dramatically during the past two decades, particularly with the increasing misuse of prescription opioids (Centers for Disease Control and Prevention (CDC), 2011, Frenk et al., 2015, Rudd et al., 2016a, Rudd et al., 2016b). Younger individuals are disproportionately affected and bear the greatest burden of premature mortality. In addition to being associated with medical illnesses such as endocarditis and hepatitis, OUDs complicate the treatment of other conditions (e.g., acute and chronic pain, conditions requiring surgical intervention) and are associated with higher costs (Birnbaum et al., 2011, Meyer et al., 2014, Ronan and Herzig, 2016).

Reducing the mortality associated with OUDs is an ongoing public health challenge and an important goal for health care systems. While health care systems have little ability to decrease some causes of premature mortality, such as injuries and homicides, they may influence mortality through the quality of the care they deliver. Health care providers can decrease the mortality risk of patients with OUDs through recognition and treatment of worsening chronic health problems, preventing iatrogenic causes of mortality or through influencing patients’ drug use and subsequent risk behaviors by providing effective treatment (Davoli et al., 2007, Gaither et al., 2016a, Gaither et al., 2016b, Grossbard et al., 2014).

Understanding the relationship between the quality of care provided and mortality can help health care systems reduce the increased mortality experienced by persons with OUDs. Quality of care is commonly examined using either measures of process, which assess the care provided to the patient, or outcomes, which assess the impact of the care on the patient’s health or functioning. While improved patient outcomes are the gold standard for measuring quality, using outcome-based quality measures is challenging. Outcome data can be expensive and difficult to obtain; do not identify which care processes need to be improved; and outcome measures require risk adjustment. In contrast, process-based measures are more easily operationalized from electronic health records and can provide information about where performance is variable and quality improvement efforts should be targeted. Furthermore, administrative-data based process measures can be reported in real-time, allowing health care systems to take timely corrective action.

While the rationale for specific quality measures usually comes from practice guidelines and/or a synthesis of the literature, process measures should have demonstrated reliability and validity before being used as quality measures to improve performance. There are no reliable and valid quality measures for individuals with OUDs, and measures that have been developed and validated for use in substance use disorders more generally have not been specifically tested in opioid dependent populations (Garnick et al., 2002, Garnick et al., 2009, Harris et al., 2010). This is an important limitation, because disease-specific measures, when they draw attention to specific clinical processes, may be more actionable than generic measures for quality improvement efforts. However, unless process measures are associated with clinically meaningful outcomes, using them to monitor and improve performance will not result in the expected improvements.

Given the importance of mortality as a clinical outcome, we examined the association of 7 process-based measures with 12- and 24-month mortality among persons with OUDs. If these measures are associated with lower mortality, it would provide initial evidence that they could be used by health care systems as part of specific strategies to improve the care provided to individuals with OUDs and to decrease mortality. It would also provide initial evidence for the predictive validity of the measures.

Section snippets

Overview

This study was approved by the Institutional Review Boards of the Central Arkansas Veterans Healthcare Center and the University of Arkansas for Medical Sciences. The boards waived the requirement for informed consent as it was a minimal risk study. Administrative data was obtained from the Veterans Administration (VA) Medical SAS data sets. Mortality through September 30, 2009 was obtained from the VA Vital Status Mini File.

Study population

We identified all veterans with OUDs using the International

Results

In FY2007, 32,422 patients with OUDs accessed services provided or paid for by the VA. Table 1 shows their demographic and descriptive characteristics; 96% were male and the average age was 52 (SD = 9). Sixty-eight percent had at least one new SUD treatment episode; 23% had co-occurring PTSD. The unadjusted mortality rate was 3.7% at 12 months (1165 individuals) and 7.2% at 24 months (2272).

Adherence to the process measures ranged from a high of 79% (any psychosocial treatment) to a low of 12%

Discussion

Among individuals with OUDs, receiving 3 of the 7 process measures was associated with lower 12- and 24-month mortality and provides initial evidence for their use as quality measures. Not being prescribed either prescription opioids or benzodiazepines, use of psychosocial treatment and quarterly physician visits were all associated with lower mortality at 12 and 24 months. It is important to note that while the population was at least minimally engaged with VA care, nearly 17% did not receive

Conclusions

At a time when health care systems are increasingly focused on measuring, assessing, and providing incentives to improve quality (Glied et al., 2015, Patel et al., 2015), the lag in the development of behavioral health measures as compared to physical health measures is concerning (Institute of Medicine, 2006). Our findings of an association between three of our seven process measures and mortality provide support for the predictive validity of these measures and for their use as quality

Role of funding source

Nothing declared.

Contributors

Each author has contributed significantly to the work and agrees to the submission. Katherine E. Watkins obtained funding, designed the study, developed quality measures, interpreted data, and drafted and edited the article. Susan M. Paddock specified statistical models, led analyses, reviewed results, and reviewed and edited the manuscript. Teresa J. Hudson oversaw the IRB review and obtaining data, reviewed results, and reviewed and edited the manuscript. Songthip Ounpraseuth conducted

Conflict of interest

No conflict declared.

Acknowledgements

This material is the result of work supported with resources and the use of facilities at the Central Arkansas Veteran Healthcare Center, Little Rock, AR. Research reported in this publication was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number R01DA033953. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The sponsors had no role in the

References (76)

  • M. Pierce et al.

    National record linkage study of mortality for a large cohort of opioid users ascertained by drug treatment or criminal justice sources in England, 2005–2009

    Drug Alcohol Depend.

    (2015)
  • B. Stein et al.

    The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone

    Drug Alcohol Depend.

    (2012)
  • M. Vogel et al.

    Treatment or high: benzodiazepine use in patients on injectable heroin or oral opioids

    Addict. Behav.

    (2013)
  • K.E. Watkins et al.

    Association between quality measures and mortality in individuals with co-occurring mental health and substance use disorders

    J. Subst. Abuse Treat.

    (2016)
  • D.P. Alford et al.

    Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience

    Arch. Intern. Med.

    (2011)
  • American Society of Addiction Medicine (ASAM)

    Standards and Performance Measures

    (2016)
  • J.M. Austin et al.

    Fostering transparency in outcomes, quality, safety, and costs

    JAMA

    (2016)
  • J.D. Baxter et al.

    Adherence to buprenorphine treatment guidelines in a Medicaid program

    Subst. Abus.

    (2015)
  • H.G. Birnbaum et al.

    Societal costs of prescription opioid abuse, dependence, and misuse in the United States

    Pain Med.

    (2011)
  • M.C. Buster et al.

    An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam

    Addiction

    (2002)
  • Centers for Disease Control and Prevention (CDC)

    Vital signs: overdoses of prescription opioid pain relievers–United States, 1999–2008

    MMWR Morb. Mortal. Wkly. Rep.

    (2011)
  • Centers for Disease Control and Prevention,

    HIV infection and HIV-associated behaviors among injecting drug users − 20 cities, United States, 2009

    MMWR Morbid. Mortal.Wkly. Rep.

    (2012)
  • F. Charlson et al.

    A systematic review of research examining benzodiazepine-related mortality

    Pharmacoepidemiol. Drug Saf.

    (2009)
  • H. Chung et al.

    Advancing Integration of Behavioral Health into Primary Care: A Continuum-Based Framework

    (2016)
  • R. Cornish et al.

    Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database

    BMJ

    (2010)
  • G. Cousins et al.

    Risk of mortality on and off methadone substitution treatment in primary care: a national cohort study

    Addiction

    (2016)
  • U. Dafni

    Landmark analysis at the 25-year landmark point

    Circ. Cardiovasc. Qual. Outcomes

    (2011)
  • M. Davoli et al.

    Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study

    Addiction

    (2007)
  • L. Degenhardt et al.

    Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies

    Addiction

    (2011)
  • L. Degenhardt et al.

    The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study

    Addiction

    (2014)
  • L. Degenhardt et al.

    Causes of death in a cohort treated for opioid dependence between 1985 and 2005

    Addiction

    (2014)
  • B.G. Druss et al.

    Quality of medical care and excess mortality in older patients with mental disorders

    Arch. Gen. Psychiatry

    (2001)
  • S. Dublin et al.

    Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study

    J. Am. Geriatr. Soc.

    (2011)
  • J.W. Finney et al.

    Why health care process performance measures can have different relationships to outcomes for patients and hospitals: understanding the ecological fallacy

    Am. J. Public Health

    (2011)
  • S.M. Frenk et al.

    Prescription opioid analgesic use among adults: United States, 1999–2012

    NCHS Data Brief

    (2015)
  • J.R. Gaither et al.

    The association between receipt of guideline-concordant long-term opioid therapy and all-cause mortality

    J. Gen. Intern. Med.

    (2016)
  • J.R. Gaither et al.

    The effect of substance use disorders on the association between guideline-concordant long-term opioid therapy and all-cause mortality

    J. Addict. Med.

    (2016)
  • S.A. Glied et al.

    Measuring performance in psychiatry: a call to action

    Psychiatr. Serv.

    (2015)
  • Cited by (18)

    • Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review

      2023, Journal of Substance Abuse Treatment
      Citation Excerpt :

      Framing these process measures in the literature around this National Committee for Quality Assurance (NCQA) HEDIS measure is important. Of note, other observational studies have found initiation and engagement process measures are associated with reduced mortality for people with AUD and other SUDs (Harris et al., 2010; Paddock et al., 2017; Watkins et al., 2016; Watkins, Ober, et al., 2017; Watkins, Paddock, et al., 2017). However, two of the trials included in this scoping review, AHEAD and CHOICE, suggested that increased engagement in alcohol-related primary management alone may not be sufficient to improve AUD-related outcomes.

    • A mixed methods study of provider factors in buprenorphine treatment retention

      2022, International Journal of Drug Policy
      Citation Excerpt :

      Several studies have documented substantial variation in buprenorphine providers’ treatment practices including urine drug testing frequency, office visit frequency, and buprenorphine dosages prescribed (Baxter et al., 2015; Knudsen et al., 2019; Yang et al., 2013). Regular office visits and receipt of any psychosocial treatment is associated in lower mortality in buprenorphine treatment, but it's unclear if these relationships are causal (Watkins et al., 2017). Identifying the source of provider-level variation in patient retention could provide insight into how to increase retention rates; however, this cannot be accomplished using claims data alone.

    • A Quality Framework for Emergency Department Treatment of Opioid Use Disorder

      2019, Annals of Emergency Medicine
      Citation Excerpt :

      Safe prescribing policies would include limits on number of days prescribed,49 adherence to outpatient care plans for patients with outpatient pain contracts, not providing opioid refills for chronic pain, and avoidance of opioid and benzodiazepine coprescribing. Decreased opioid and benzodiazepine coprescribing to patients with opioid use disorder has been shown to have mortality benefit.50 ED-relevant quality measures in this domain may be focused on structural and process measures because patient outcomes, such as development of opioid use disorder, are distal in relation to the time of the ED visit.

    • Developing an opioid use disorder treatment cascade: A review of quality measures

      2018, Journal of Substance Abuse Treatment
      Citation Excerpt :

      Although some patients may receive high quality care for other SUDs that does not involve MAT, the evidence does not currently support this as a first line approach for OUD. Additionally, studies such as Watkins, Paddock, et al., 2017 have demonstrated the limitations of general SUD measure reliability for OUD and pitfalls of their misapplication to OUD, limiting clinical validity. For example, in many systems, the initiation of MAT may reflect underlying addiction severity requiring risk adjustment as a confounder for outcomes such as mortality in addition to serving as a process measure approximating quality care.

    View all citing articles on Scopus
    View full text